Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 98 citing articles:

Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae
Jesús Rodríguez‐Baño, Belén Gutiérrez‐Gutiérrez, Isabel Machuca, et al.
Clinical Microbiology Reviews (2018) Vol. 31, Iss. 2
Open Access | Times Cited: 601
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
Mical Paul, Elena Carrara, Pilar Retamar, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 4, pp. 521-547
Open Access | Times Cited: 598
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, et al.
Clinical Infectious Diseases (2023)
Open Access | Times Cited: 481
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 2, pp. 187-212
Open Access | Times Cited: 347
Epidemiology, definition and treatment of complicated urinary tract infections
Florian Wagenlehner, Truls E. Bjerklund Johansen, Tommaso Cai, et al.
Nature Reviews Urology (2020) Vol. 17, Iss. 10, pp. 586-600
Closed Access | Times Cited: 242
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
Pranita D. Tamma, Emily L. Heil, Julie Ann Justo, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 161
A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli
Sina Nasrollahian, Jay P. Graham, Mehrdad Halaji
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 35
Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents
Mazen S. Bader, Mark Loeb, Daniela Leto, et al.
Postgraduate Medicine (2019) Vol. 132, Iss. 3, pp. 234-250
Closed Access | Times Cited: 141
Carbapenem-Sparing Strategies for ESBL Producers: When and How
Ilias Karaiskos, Helen Giamarellou
Antibiotics (2020) Vol. 9, Iss. 2, pp. 61-61
Open Access | Times Cited: 117
Antibiotic stewardship in the ICU: time to shift into overdrive
David Mokrani, Juliette Chommeloux, Marc Pineton de Chambrun, et al.
Annals of Intensive Care (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 25
Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?
Zoi Dorothea Pana, Theoklis Zaoutis
F1000Research (2018) Vol. 7, pp. 1347-1347
Open Access | Times Cited: 74
Guidelines for Antibiotic Prescription in Intensive Care Unit
Randeep Guleria, Anant Mohan, Atul P Kulkarni, et al.
Indian Journal of Critical Care Medicine (2019) Vol. 23, Iss. S1, pp. 1-63
Open Access | Times Cited: 59
Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase–Producing Organisms?
Sima L. Sharara, Joe Amoah, Zoi Dorothea Pana, et al.
Clinical Infectious Diseases (2019) Vol. 71, Iss. 8, pp. e331-e337
Open Access | Times Cited: 55
Current and Emerging Treatment Options for Multidrug Resistant Escherichia coli Urosepsis: A Review
Mikaela M. Walker, Jason A. Roberts, Benjamin A. Rogers, et al.
Antibiotics (2022) Vol. 11, Iss. 12, pp. 1821-1821
Open Access | Times Cited: 27
Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis
Florian Wagenlehner, Verónica Rico Caballero, Vikalp Kumar Maheshwari, et al.
Journal of Comparative Effectiveness Research (2025) Vol. 14, Iss. 3
Closed Access
Antimicrobial Resistance and Mortality in Carbapenem-Resistant Pseudomonas aeruginosa Infections in Southern Thailand
Parichart Chotimakorn, Sutthiporn Pattharachayakul, Yongyut Lertsrisatit, et al.
Antibiotics (2025) Vol. 14, Iss. 3, pp. 322-322
Open Access
Cefepime versus carbapenem for treating complicated urinary tract infection caused by cefoxitin-nonsusceptible ESCPM organisms: a multicenter, real-world study
Liang Chen, Jie Hua, Xiaopu He
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access
Management of infections caused by extended-spectrum β–lactamase-producingEnterobacteriaceae: current evidence and future prospects
Chau‐Chyun Sheu, Shang‐Yi Lin, Ya-Ting Chang, et al.
Expert Review of Anti-infective Therapy (2018) Vol. 16, Iss. 3, pp. 205-218
Closed Access | Times Cited: 45
Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review
Sarah Melissa Nørgaard, Camilla Skaarup Jensen, Josefine Aalestrup, et al.
Antimicrobial Resistance and Infection Control (2019) Vol. 8, Iss. 1
Open Access | Times Cited: 38
Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis
C. Nguyen, Thuc Nguyen Dan, Roger J. M. Brüggemann, et al.
International Journal of Antimicrobial Agents (2019) Vol. 54, Iss. 6, pp. 790-797
Closed Access | Times Cited: 35
Unmet Needs in Complicated Urinary Tract Infections: Challenges, Recommendations, and Emerging Treatment Pathways
Joanna Marantidis, Rachael D. Sussman
Infection and Drug Resistance (2023) Vol. Volume 16, pp. 1391-1405
Open Access | Times Cited: 11
Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms
Audrey N. Schuetz, Sergio Reyes, Pranita D. Tamma
Journal of Clinical Microbiology (2017) Vol. 56, Iss. 3
Open Access | Times Cited: 34
Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017).
Rafael Cantón, Elena Loza, Javier Aznar, et al.
PubMed (2019) Vol. 32, Iss. 2, pp. 145-155
Closed Access | Times Cited: 30
Healthcare-associated urinary tract infections in urology.
José Medina‐Polo, Kurt G. Naber, Truls E. Bjerklund Johansen
DOAJ (DOAJ: Directory of Open Access Journals) (2021) Vol. 9, pp. Doc05-Doc05
Closed Access | Times Cited: 24
Mortality and its predictors among hospitalized patients with infections due to extended spectrum beta-lactamase (ESBL) Enterobacteriaceae in Malaysia: a retrospective observational study
Usman Abubakar, Balamurugan Tangiisuran, Mohamed Hassan Elnaem, et al.
Future Journal of Pharmaceutical Sciences (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top